Sinovac and Parenteral Biotech Enter Supply and Distribution Agreement for India
Sinovac Biotech, Ltd. (Beijing, China), a vaccine manufacturer, has signed an exclusive license, supply, and distribution agreements with Parenteral Biotech Ltd., a subsidiary of Parenteral Drugs (India), Ltd., an India-based pharmaceutical company.
Sinovac Biotech, Ltd. (Beijing, China), a vaccine manufacturer, has signed an exclusive license, supply, and distribution agreements with Parenteral Biotech Ltd., a subsidiary of Parenteral Drugs (India), Ltd., an India-based pharmaceutical company. According to the agreements, Parenteral is authorized to register, supply, and distribute Sinovac’s Anflu (seasonal influenza vaccine) and PANFLU.1 (H1N1 vaccine) to the government and private market in India. The registration process currently is ongoing in India.
Parenteral intends to apply to the Drug Controller General of India for the import approval for the vaccines. The volume, delivery schedule, and other specific details about how Sinovac’s vaccines may be marketed and supplied to the government of India and the private market in India have not been determined.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
FDA Reopens Comment Period on HCP Immunogenicity Risk of Follow-on Recombinant Peptides
January 2nd 2025FDA is reopening the comment period for the Federal Register Notice, “Evaluating the Immunogenicity Risk of Host Cell Proteins in Follow-on Recombinant Peptide Products: Establishment of a Public Docket: Request for Information and Comments”, until March 3, 2025.
